Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancer.
In this retrospective study the relationship between serum prostate-specific antigen (PSA) and tumour volume (assessed by the planimetric method on whole mount section) was analysed in 56 patients subjected to radical prostatectomy, of whom 28 received 3 months of neoadjuvant GnRH analogue (triptorelin) treatment. Serum PSA in the control group was strongly correlated to the tumour volume while no such correlation was found after hormonal pretreatment (r = 0.84 vs. 0.18), indicating that serum PSA is unreliable as a tumour marker after hormonal deprivation. When the pretreatment PSA (before hormonal deprivation) per tumour volume ratio was calculated, a group of 10 patients (36%) showed considerably higher values, suggesting true tumour volume reduction in those patients as a result of the neoadjuvant hormonal treatment.
Aus
G
G
Division of Urology, Ostra Hospital, University of Göteborg, Sweden.
Brändstedt
S
S
Häggman
M
M
Pedersen
K
K
de la Torre
M
M
Hugosson
J
J
D014408:Biomarkers, Tumor / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D017373:Cyproterone Acetate / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
D014408:Biomarkers, Tumor; D017329:Triptorelin Pamoate; D017373:Cyproterone Acetate; D017430:Prostate-Specific Antigen